BrainStorm's Pivotal ALS Trial Faces Funding Hurdle After Low Cash Report
Summary
BrainStorm Cell Therapeutics reported full-year 2025 financial results, revealing a critically low cash balance of approximately $0.3 million as of December 31, 2025. While the company subsequently secured $2 million in financing through private placements in February 2026, its planned Phase 3b ENDURANCE study for NurOwn in ALS remains "pending funding." This is a significant concern for a micro-cap clinical-stage biotech, as the ability to fund and initiate its pivotal trial is paramount to its valuation and future prospects. Despite positive updates on durable long-term survival in an Expanded Access Program cohort and prior FDA clearance for the study, the current financing is likely insufficient for a full Phase 3b trial, overshadowing these positive developments. Investors will be closely monitoring for news of substantial additional financing to enable the progression of this critical clinical program.
At the time of this announcement, BCLI was trading at $0.95 on OTC in the Life Sciences sector, with a market capitalization of approximately $10.5M. The 52-week trading range was $0.46 to $1.92. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.